FDA Approves Fourth Alzheimer’s Blood Test in Under Two Years
The FDA has approved a new blood test for Alzheimer's disease. This is the fourth such blood test approval in under two years.
Cleveland Akron, OH, August 24, 2026 —
The U.S. Food and Drug Administration (FDA) has announced the approval of a new blood test designed to detect Alzheimer’s disease. This marks the fourth such diagnostic tool to receive FDA authorization within the last two years, signaling a significant acceleration in the development and availability of accessible methods for diagnosing the neurodegenerative condition.
Details regarding the specific name of the newly approved test, the company responsible for its development, and its precise diagnostic capabilities were not immediately available. However, the approval follows a recent trend of increasing regulatory authorization for blood-based diagnostics for Alzheimer’s.
Previously, three other blood tests for Alzheimer’s disease have been approved by the FDA in a relatively short period. These advancements represent a shift from traditional diagnostic methods, which often involved costly and invasive procedures such as PET scans or cerebrospinal fluid analysis.
Blood tests offer a potentially less invasive, more convenient, and more widely accessible option for screening and diagnosis. Their increasing availability is expected to aid healthcare providers in identifying individuals with Alzheimer’s disease earlier, potentially leading to more timely interventions and management strategies. Further information on the specific performance metrics and target populations for this latest approved test is anticipated.
Story summarized from the original created by Joseph Choi and The Hill on fox8.com, see more information here.
